Small molecule glucokinase activators as novel anti-diabetic agents.
The monomeric enzyme GK (glucokinase) has a low affinity for glucose and, quantitatively, is largely expressed in the liver and pancreatic beta-cells, playing a key 'glucose sensing' role to regulate hepatic glucose balance and insulin secretion. Mutations of GK in man can be inactivating, to cause a form of diabetes mellitus, or activating, to lower blood glucose levels. Recently, models of GK protein structure have helped to elucidate the role of inactivating and activating mutations, with the latter revealing an allosteric binding site, possibly for an unknown physiological activator. However, this discovery was pre-dated by Drug Discovery projects that have identified small organic molecules that activate pancreatic and liver GK enzyme activity. These compounds stimulate insulin secretion in islets and glucose metabolism in hepatocytes. The profile of these GK activators, both in vitro and in vivo and the potential role that GK activators play in lowering blood glucose levels in Type II diabetes mellitus will be discussed.
Leighton
B
B
AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. Brendan.Leighton@astrazeneca.com
Atkinson
A
A
Coghlan
M P
MP
D000818:Animals; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology*; D004789:Enzyme Activation / Q000187:drug effects; D005941:Glucokinase / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism
D007004:Hypoglycemic Agents; D007328:Insulin; D005941:Glucokinase; D005947:Glucose